Canada Research Chair in Diabetes and Pancreatic ß-cell Function

Canada Research Chair in Diabetes and Pancreatic β-cell Function

The present invention provides a recombinant, glucose-regulated insulin producing beta cell whose proliferation is controlled by tetracycline or a derivative thereof.

New discovery in beta-cell pathway shows potential to improve effectiveness of diabetes drugs

And the second finding from this research was that the pancreas became able to compensate the loss of insulin-producing beta cells.

The second major discovery was that pancreas can compensate for the loss of insulin-producing beta cells.

Activation of GLP1R with these drugs helps the beta cell produce and secrete more insulin.

The loss of pancreatic beta cells, responsible for the production of insulin hormone, is considered to be the main factor.

Understanding the processes that influence beta cell function is central to understanding how diabetes develops.

In type 1 diabetes, the pancreatic beta cell is targeted by auto-immune cytotoxic T lymphocytes.

This model now allows us to study which factors are expressed in a cell dedifferentiated beta, and what mechanisms are involved.

In response to infection, the beta cell displays an antigen on its surface which is detected by the immune system.

Insulin resistance is a central feature of type II diabetes and other diseases, and may affect every tissue of the body, including the pancreatic beta cell.

At the heart of pancreatic beta cells, Drs. Koppe and Poitout identified a particular protein, called phosphofruktokinase 1.

At the heart of pancreatic beta cells, Drs. Koppe and Poitout identified a particular protein, called phosphofruktokinase 1.